GDF8 Promotes the Cell Invasiveness in Human Trophoblasts by Upregulating the Expression of Follistatin-Like 3 Through the ALK5-SMAD2/3 Signaling Pathway

Jiamin Xie¹, Hua Zhu¹, Hsun-Ming Chang¹, Christian Klausen¹, Minyue Dong²,3,4* and Peter C. K. Leung¹*

¹ Department of Obstetrics and Gynaecology, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada, ² Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China, ³ Key Laboratory of Women’s Reproductive Health of Zhejiang Province, Hangzhou, China, ⁴ Key Laboratory of Reproductive Genetics, Ministry of Education, Hangzhou, China

Growth differentiation factor 8 (GDF8) and its antagonist follistatin-like 3 (FSTL3) are expressed in the placenta during early pregnancy. These two factors may have a role to play in the regulation of normal placentation. However, whether GDF8 can regulate the expression of FSTL3 in human trophoblasts remains to be elucidated. In this study, we aimed to investigate the effects of GDF8 on the expression of FSTL3 and the underlying molecular mechanisms using human trophoblasts as a study model. Our results showed that GDF8 significantly upregulates the expression and production of FSTL3, which further promotes cell invasiveness in immortalized extravillous cytotrophoblast cells and primary extravillous cytotrophoblast cells obtained from human first-trimester placentae. Additionally, using an siRNA-mediated knockdown approach, we found that this regulatory effect is most likely mediated by the ALK5-Sma- and Mad-related protein (SMAD)2/3-induced signaling pathway. These findings deepen our understanding of the functional roles of GDF8 and FSTL3 in the regulation of cell invasiveness of trophoblasts.

Keywords: GDF8, follistatin-like 3, extravillous cytotrophoblast, trophoblast invasion, ALK5, SMAD2/3

INTRODUCTION

Trophoblasts play key roles in the regulation of embryo development and implantation, as well as in the maintenance of normal pregnancy (Staun-Ram and Shalev, 2005). These cells influence multiple physiological and pathological conditions by releasing various factors into the placental and maternal circulation (Bischof and Campana, 2000). Among several trophoblast cells, extravillous trophoblasts (EVTs) invade into the decidual layer of the uterus and participate in the remodeling of the uterine spiral arteries, which subsequently achieve the high-flow, low-resistance circulation characteristic of the intervillous space of the term placenta (Loke et al., 1995; Burrows et al., 1996). At approximately 10 weeks of gestation, the maternal blood flows to the placenta due to successful EVT invasion, leading to the establishment of the exchange of nutrients and gasses...
between maternal and fetal circulations (Fest et al., 2007). Inadequate remodeling of maternal arteries or improper trophoblast invasion can result in insufficient uterine placental perfusion and induce several pregnancy-related complications, including preeclampsia and fetal growth restriction (Redman and Sargent, 2005; Burton et al., 2009). In contrast, excessive trophoblast invasion may lead to placenta creta (accreta, increta, and percreta) or gestational trophoblastic diseases (Allias et al., 2015; Silva and Serakides, 2016).

Members of the transforming growth factor β (TGF-β) superfamily play important roles in the regulation of trophoblast invasion and placentalization (Adu-Gyamfi et al., 2020). As a secreted protein of the TGF-β superfamily, growth differentiation factor 8 (GDF8, also known as myostatin; McPherron et al., 1997) is expressed in EVTs and has been shown to promote trophoblast migration (Peiris et al., 2014). Although studies have shown that GDF8 acts to facilitate glucose uptake during placentation (Peiris and Mitchell, 2012), the detailed molecular mechanisms remain to be elucidated. Similar to other members of the TGF-β superfamily, GDF8 initiates its cellular activities by binding to two TGF-β type II receptors, which further phosphorylate two TGF-β type I receptors (functional serine/threonine kinase receptors; Graham and Peng, 2006; Neuzillet et al., 2014). Upon the ligand-receptor interaction, the complex delivers the signal through the phosphorylation of canonical (or non-canonical) SMAD (Sma- and Mad-related protein) proteins, which subsequently modulate the expression of the targeted genes (Shi and Massagué, 2003).

Follistatin-like 3 (FSTL3, also known as follistatin-related gene) is a regulatory glycoprotein that acts as an antagonist to bind to members of the TGF-β superfamily, including activins and GDF8 (Schneyer et al., 2004). In particular, FSTL3 has a high affinity to bind to GDF8 (Tsuchida, 2004). In the human placenta, the overall level of FSTL3 is approximately 2-20 times higher than compared with other organs (The Human Protein Atlas1), followed by testes, heart, and pancreas (Tortoriello et al., 2001). Studies have shown that the maternal serum levels and placental expression of FSTL3 and GDF8 were significantly increased in women with preeclampsia (Guo et al., 2012; Founds et al., 2015; Horvath et al., 2016). Data obtained from clinical samples showed that FSTL3 was elevated in the second trimester, which was associated with an increased risk in developing preeclampsia (Founds et al., 2015). Furthermore, we have demonstrated that the expression of FSTL3 is upregulated in trophoblasts under the stimulus of hypoxia (one of features of preeclampsia) and that the lack of FSTL3 inhibits trophoblast invasion (Xie et al., 2018). These findings indicate that GDF8 and FSTL3 might play a role in the regulation of normal placentalization and in preeclampsia.

Given the spatiotemporal changes in the expression of GDF8 and FSTL3 in the placenta during pregnancy, we proposed that GDF8 may modulate the expression and production of FSTL3 in human trophoblasts. In this study, we aimed to investigate the regulatory effects of GDF8 on the expression and function of FSTL3 and the underlying molecular mechanisms using human trophoblast cells as a study model.

### MATERIALS AND METHODS

#### Culture of Immortalized Human EVT Cells

The HTR8/SVneo (derived by transfecting the cells that grew out of chorionic villi explants of human first-trimester placenta with the gene encoding for simian virus 40 large T antigen) human EVT cell line (Graham et al., 1993) used in this study was a gift kindly supplied by Dr. P. K. Lala (Western University, Canada), and the cells were grown in DMEM (Invitrogen, Life Technologies, Carlsbad, CA, United States) containing 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin (Life Technologies). A total of 1 × 10^6 HTR8/SVneo cells were seeded per 60 mm² culture dish for GDF8 (reconstituted by the solvent of sterile 4 mM HCl containing at least 0.1% bovine serum albumin) treatment in a concentration-dependent (10, 25, and 50 ng/ml) or time-dependent (3, 6, 12, 24, and 48 h) manner. The solvent of 4 mM HCl containing at least 0.1% bovine serum albumin was used as a vehicle control.

#### Isolation and Culture of Human Primary EVT Cells

This study was approved by the Research Ethics Board of the University of British Columbia. First-trimester human placentae (at 6–9 weeks of gestation) were isolated individually from women who gave informed consent and were undergoing elective termination of pregnancy. The EVT cells were collected from explanted human chorionic villi as previously described (Irving et al., 1995; Li et al., 2014). Approximately 99% of the isolated primary EVT cells that were used in this study were immunocytochemically positive for both cytokeratin-7 and HLA-G (Chen et al., 2012). A total of 7 × 10^5 HTR cells were seeded per 60 mm² culture dish for GDF8 treatment in a concentration-dependent or time-course manner.

#### Matrigel-Coated Transwell Cell Invasion Assay

Cell invasiveness ability was assessed using the Matrigel-coated transwell invasion assay (Justus et al., 2014; Li et al., 2015). Briefly, the Matrigel chamber was prepared by pipetting 40 µL diluted growth factor-reduced Matrigel solution (1 mg/mL; BD Biosciences) on the top of transwell inserts (pore size, 8 µm; for 24-well use, BD Biosciences, San Jose, CA, United States), and then the insert was gently rotated to ensure that the entire filter was coated. A total of 1 × 10^5 cells suspended in 250 µL DMEM supplemented with 0.1% FBS were seeded in the upper chamber of 24-well transwell inserts, and 750 µL of medium with 10% FBS was added to the lower chamber. The cells were then incubated at 37°C for 48 h. After incubation for 48 h, cells that invade into the lower chamber through the pores in the membranes were fixed with cold 70% methanol in −20°C for 20 min, washed by PBS for three times and stained with the Hoechst 33,258 (Sigma-Aldrich, Oakville, ON, Canada). The excess cells on the surface of the membranes were erased by the cotton swab, and then observed using a Zeiss Axioshot epifluorescence microscope and Northern Eclipse 6.0 software (Empix Imaging, Inc., Cheektowaga, NY, United States). Views underneath the

1https://www.proteinatlas.org/ENSG00000070404-FSTL3/tissue
Gene | Forward primer sequence | Reverse primer sequence
--- | --- | ---
FSTL3 | 5′-CTCACATTCTCTC | 5′-TCTGTCGACAGACT
GAPDH | 5′-GGTCCACAAC-3′ | CACCACT-3′
ALK5 | 5′-GAGTCAACGGAT | 5′-GACAAGCTTCCC
ALK4 | 5′-GCCTTTACAGCTTC | 5′-ATGTGGCAATCCT
ALK3 | 5′-CTTCTGCAGACT | 5′-GGTTCTCAG-3′
ALK2 | 5′-GACAAGCTTCCC | 5′-GGTTCTCAG-3′
ALK1 | 5′-ACACTTCCTC | 5′-GGTTCTCAG-3′

FSTL3, follistatin-like 3.
GDF8 Promotes Trophoblast Invasion

FIGURE 1 | Growth differentiation factor 8 (GDF8) promotes cell invasion in HTR8/SVneo and primary extravillous trophoblast (EVT) cells. HTR8/SVneo (A) or primary EVT (B) cells were treated for 48 h with the vehicle control (Ctrl) or 25 ng/mL GDF8, and cell invasion was examined using the Matrigel-coated transwell assay. The results are displayed as the mean ± SEM of at least three independent experiments, and the values with different letters are significantly different (\( P < 0.05 \)).

and primary EVT cells (Figures 2A,C,E,G). A time-dependent study showed that GDF8 (25 ng/mL) increased the mRNA levels as well as the accumulation of FSTL3 in HTR8/SVneo at all the time points tested (Figures 2B,D). Whereas in primary EVT cells, significant increase of FSTL3 were observed at 24 h at both mRNA and protein levels by GDF8 treatment (Figures 2F,H).

FSTL3 Mediates the GDF8-Induced Increase in Cell Invasiveness in HTR8/SVneo and Primary EVTs

To determine whether FSTL3 is involved in GDF8-induced increase in cell invasiveness in human trophoblasts, we used siRNA-based depletion to knock down endogenous FSTL3. The quantification of the knockdown efficiency using RT-qPCR showed that transfection with siRNAs targeting FSTL3 (siFSTL3) significantly decreased the basal levels of FSTL3 as well as the GDF8-induced FSTL3 levels in HTR8/SVneo compared to the non-targeting group (Figures 3A,B). Similar results were obtained in primary EVT (Figures 3D,E) cells. Notably, siRNA knock-down of FSTL3 decreased basal trophoblast cell invasiveness and completely abolished the GDF8-induced increase in cell invasiveness in HTR8/SVneo (Figure 3C) and primary EVT (Figure 3F) cells. These results indicate that FSTL3 is the key factor that mediates the stimulatory effect of GDF8 on cell invasiveness in human trophoblast cells.

GDF8 Activates SMAD2/3 Signaling in HTR8/SVneo and Primary EVT Cells

To investigate the downstream molecular signaling involved, HTR8/SVneo and primary EVT cells were treated with exogenous GDF8 for 30 or 60 min, respectively. The western blot analysis showed that treatment with GDF8 (25 ng/mL) significantly increased the phosphorylation of SMAD2 in both HTR8/SVneo (Figure 4A) and primary EVT (Figure 4C) cells. Similarly, significant elevation of SMAD3 phosphorylation were also observed in both HTR8/SVneo (Figure 4B) and primary EVT (Figure 4D) cells.

ALK5 Is the Principal Type I Receptor That Mediates the GDF8-Induced Increases in SMAD2/3 Phosphorylation and Cell Invasiveness in Trophoblast Cells

Previous studies have shown that GDF8 initiates its cellular activities by binding to the activin type I receptors (Attisano et al., 1993) and type II receptors, which further activates the SMAD signaling pathway (Lee and McPherron, 2001; Rebbapragada et al., 2003). To determine which type I receptor mediates the GDF8-induced cellular activities in human trophoblasts, we depleted ALK4 or ALK5 by siRNA knockdown.
Xie et al. GDF8 Promotes Trophoblast Invasion

FIGURE 2 | Growth differentiation factor 8 (GDF8) upregulates the expression of follistatin-like 3 (FSTL3) in HTR8/SVneo and primary EVT cells. **A,C,E,** and **G:** HTR8/SVneo (**A,C**) or primary EVT (**E,G**) cells were treated for 24 h with the vehicle control (Ctrl) or different concentrations (10, 25, or 50 ng/mL) of GDF8; the mRNA (**A,E**) and accumulated (**C,G**) levels of FSTL3 were examined using RT-qPCR and ELISA, respectively. **B,D,F,** and **H:** HTR8/SVneo (**B,D**) or primary EVT (**F,H**) cells were treated with the vehicle control (Ctrl) or 25 ng/mL GDF8 for 3, 6, 12, 24, or 48 h; the mRNA (**B,F**) and accumulated (**D,H**) levels of FSTL3 were examined using RT-qPCR and ELISA, respectively. The results are displayed as the mean ± SEM of at least three independent experiments, and the values with different letters are significantly different (P < 0.05).

strategy in HTR8/SVneo cells, respectively. The knockdown efficiency showed that transfection with siRNAs targeting ALK4 (siALK4) or ALK5 (siALK5) significantly decreased the specific mRNA level of ALKs (**Figures 5A,B**) in HTR8/SVneo cells. Remarkably, knockdown of ALK5 completely abolished the GDF8-induced phosphorylation of SMAD2 and SMAD3 (**Figures 5C,D**). In contrast, the phosphorylation of SMAD2 and SMAD3 were not affected by ALK4 depletion (**Figures 5C,D**). Furthermore, knock-down of ALK5 completely attenuated the GDF8-induced effects on the mRNA and accumulated levels of FSTL3 (**Figure 5E,F**). Most importantly, knockdown of ALK5 completely abolished the GDF8-induced increase in cell invasiveness in HTR8/SVneo cells (**Figure 5G**). These results indicate that ALK5, but not ALK4, is the principal type I receptor
that mediates the GDF8-induced increase in cell invasiveness in human trophoblast cells.

**SMAD2 and SMAD3 Are the Downstream Mediators of the GDF8-Induced Upregulation of FSTL3 Expression**

In mammals, SMAD2 and SMAD3 share a similar structure and act redundantly during skeletal development and regeneration (Song et al., 2009). The siRNA-based depletion of endogenous SMAD2 and SMAD3 were used to determine which SMAD is involved in the GDF8-induced upregulation of FSTL3 expression. As shown in Figures 6A–D, transfection with 20 nM siSMAD2 or 20 nM siSMAD3 for 24 h significantly decreased the mRNA and protein levels of the target SMAD, respectively, in HTR8/SVneo cells. Knocking down SMAD2 completely abolished the stimulatory effect of GDF8 on the mRNA expression and protein production of FSTL3 in HTR8/SVneo cells (Figures 6E,F). Similar results were observed on FSTL3 levels by siSMAD3 knockdown in HTR8/SVneo cells.
FIGURE 4 | Growth differentiation factor 8 (GDF8) increases the phosphorylated protein levels of SMAD2 and SMAD3 in HTR8/SVneo and primary EVT cells. HTR8/SVneo (A,B) or primary EVT (C,D) cells were treated for 30 or 60 min with the vehicle control (Ctrl) or 25 ng/mL GDF8. The phosphorylated protein levels of SMAD2 (A,C) and SMAD3 (B,D) were examined using western blot analysis. SMAD2 and SMAD3 were used as the loading control and references for densitometric analysis for p-SMAD2 and p-SMAD3, respectively. The results are displayed as the mean ± SEM of at least three independent experiments, and the values with different letters are significantly different (P < 0.05).

(Figures 6G,H). Taken together, these observations indicate that both SMAD2 and SMAD3 are the downstream mediators of the GDF8-induced upregulation of FSTL3 expression in HTR8/SVneo cells.

DISCUSSION

The expression of GDF8 is dramatically changed with gestational age (Mitchell et al., 2006). It has been reported that the expression of GDF8 is significantly higher in early and preterm placentae compared with the term placentae; this phenomenon is most likely correlated to its trophoblast invasion ability (Peiris and Mitchell, 2012). Indeed, the aberrant expression of GDF8 has been observed in many diseases, such as obesity, type 2 diabetes, and preeclampsia (Hittel et al., 2009; Palsgaard et al., 2009; Brandt et al., 2012; Guo et al., 2012). In particular, the expression levels of GDF8 are much higher in patients with preeclampsia (Guo et al., 2012). Preeclampsia is a complex multisystem pregnancy-specific disorder that is characterized
FIGURE 5 | ALK5 mediates the growth differentiation factor 8 (GDF8)-induced increase in phosphorylated protein levels of SMAD2/3 and cell invasion in HTR8/SVneo cells. **(A,B)** HTR8/SVneo cells were transfected for 24 h with 20 nM non-targeting control siRNAs (siCtrl), 20 nM siRNAs targeting ALK4 (siALK4) or 20 nM siRNAs targeting ALK5 (siALK5), after which the cells were treated with the vehicle control (Ctrl) or 25 ng/mL GDF8 for 24 h; the mRNA levels of ALK4 (**A**) and ALK5 (**B**) were examined using RT-qPCR. **(C,D)** HTR8/SVneo cells were transfected for 24 h with 20 nM siCtrl, 20 nM siALK4, or 20 nM siALK5, after which the cells were treated with the vehicle control (Ctrl) or 25 ng/mL GDF8 for 30 or 60 min; the phosphorylated protein levels of SMAD2 (**C**) and SMAD3 (**D**) were examined using western blot analysis. **(E–G)** HTR8/SVneo cells were transfected for 24 h with 20 nM siCtrl or 20 nM siALK5, after which the cells were treated with the vehicle control (Ctrl) or 25 ng/mL GDF8 for 24 h; the mRNA (**E**) and accumulated (**F**) levels of follistatin-like 3 (FSTL3) were examined using RT-qPCR and ELISA, respectively, and cell invasion was examined using the Matrigel-coated transwell assay. SMAD2 and SMAD3 were used as the loading control and references for densitometric analysis for p-SMAD2 and p-SMAD3, respectively. The results are displayed as the mean ± SEM of at least three independent experiments, and the values with different letters are significantly different (P < 0.05).
FIGURE 6 | SMAD2 and SMAD3 are the downstream mediators of the growth differentiation factor 8 (GDF8)-induced upregulation of follistatin-like 3 (FSTL3) expression in HTR8/SVneo cells. (A–D) HTR8/SVneo cells were transfected for 24 h with 20 nM non-targeting control siRNAs (siCtrl), 20 nM siRNAs targeting SMAD2 (siSMAD2) or 20 nM siRNAs targeting SMAD3 (siSMAD3), after which the cells were treated with the vehicle control (Ctrl) or 25 ng/mL GDF8 for 24 h; the mRNA and protein levels of SMAD2 (A,B) and SMAD3 (C,D) were examined using RT-qPCR and western blot analysis, respectively. (E–H) HTR8/SVneo cells were transfected for 24 h with 20 nM siCtrl, 20 nM siSMAD2 (E,F) or 20 nM siSMAD3 (G,H), after which the cells were treated with the vehicle control (Ctrl) or 25 ng/mL GDF8 for 24 h; the mRNA (E,G) and accumulated (F,H) levels of FSTL3 were examined using RT-qPCR and ELISA, respectively. GAPDH used as the loading control and a reference for densitometric analysis for SMAD2 and SMAD3. The results are displayed as the mean ± SEM of at least three independent experiments, and the values with different letters are significantly different (P < 0.05).
by the development of hypertension and proteinuria after 20 weeks of gestation (Duley, 2009). In our previous studies, we observed that the serum levels and placental expression of FSTL3 were significantly increased in women with preeclampsia (Han et al., 2014). Moreover, we found that the expression of FSTL3 in trophoblasts were increased under hypoxic culture conditions and that this increased expression is involved in the regulation of trophoblast functions, including cell invasion, migration, lipid storage, and apoptosis (Xie et al., 2018). With regard to the pathogenesis of preeclampsia, the main etiology is the inadequate trophoblast cell invasion into the uterine vessel (Schneyer et al., 2004; Karumannchi and Stillman, 2006). In this regard, an understanding of the regulatory process of trophoblast invasion and the role of FSTL3 in trophoblast invasion will facilitate the development of diagnostic strategies for preeclampsia. In this follow-up study, we demonstrated that GDF8 promotes the expression and production of FSTL3 in human trophoblasts, including an immortalized cell line and cultured primary extravillous cytotrophoblasts isolated from the first-trimester placenta. Furthermore, we found that siRNA knock-down of FSTL3 completely abolished the GDF8-induced increase in cell invasiveness, indicating that FSTL3 is a mediator that promotes trophoblast invasion in humans. As an antagonist of the TGF-β superfamily members, FSTL3 mainly acts to inhibit the cellular activities in response to activins and GDF8 (Schneyer et al., 2004; Tsuchida, 2004). This statement of the issue raises a question of how both molecules act in parallel to promote trophoblast invasion. If FSTL3 is the antagonist of GDF8, then a negative feedback should oppose or subtract the GDF8-induced cellular activities in such a way as to counteract the change. However, previous studies have shown that FSTL3 can also function as a proinflammatory cytokine that regulates the expression of multiple factors, including CD36, lectin-like oxLDL receptor-1, interleukin 1-β, monocyte chemoattractant protein 1, tumor necrosis factor-α, and matrix metalloproteinase-9 (MMP-9) in the immune system (Runhua et al., 2019). MMP-9, a metal-dependent endopeptidase, is capable of degrading the extracellular matrix, which plays an essential role in trophoblast invasion (Zhu et al., 2012). Specifically, MMP-9 is strongly expressed in human EVTs at the placental bed at 6–8 weeks of gestation and this protein appears to regulate trophoblast invasion (Zhu et al., 2012). In this regard, FSTL3 may mediate the GDF8-induced increase in cell invasiveness through the upregulation of MMP-9 in human trophoblasts. It is most likely that the antagonist effect of FSTL3 on MMP-9 is more prominent than that on GDF8 in terms of trophoblast invasiveness. In fact, GDF8 and FSTL3 are both induced and increased in patients with preeclampsia by a defective trophoblast invasion. Thus, the relative expression levels of these factors could be a determinant of clinical outcome of preeclampsia. Similarly, activin A and FSTL3 have been shown to be induced in heart by myocardial stress (Oshima et al., 2009). Future studies using animal models to investigate the role of FSTL3 in the regulation of extracellular matrix remodeling-related enzymes will be of great interest. Specifically, we would like to generate trophoblast-specific conditional Fstl3 knockout (or knockin) mice and investigate the functional changes in trophoblasts, including trophoblast proliferation, migration and invasion, spiral artery remodeling, and placentation.

In the in vivo system, the interaction between GDF8 and FSTL3 is more complicated than we expected, especially when we discuss their roles in the development of preeclampsia. There are dynamic changes in the expression patterns of GDF8 and FSTL3 during different stages of gestation. In the early stage, Peiris et al. (2015) collected the samples from pre-symptomatic women who later developed preeclampsia in the early second trimester and found that plasma concentrations of GDF8 were significantly elevated. As the antagonist of GDF8, FSTL3 was under-expressed in the first trimester placental tissues of preeclampsia (Founds et al., 2011). During the first half of human pregnancy, the endothelium and smooth muscle cells of uteroplacental arteries have been apparently replaced by invasive trophoblasts (Kaufmann et al., 2003). In this period, FSTL3 was decreased, while GDF8 was increased, indicating that the lack of FSTL3 might be a potential pathogenic factor of preeclampsia as the decreased level of FSTL3 insufficiently induced trophoblast invasion. However, during the later stage of gestation, maternal serum levels of both FSTL3 and GDF8 were significantly elevated in women with preeclampsia. Guo et al. (2012) reported that the basal levels of GDF8 were approximately 30 µg/ml in normal pregnant women and 45 µg/ml in women with preeclampsia; whereas, those of FSTL3 were 50 ng/ml in normal pregnant women and 300 ng/ml in women with preeclampsia. These results indicate that the dynamic change in FSTL3 in women with preeclampsia is much less than that in GDF8, thus the antagonist effect of FSTL3 on GDF8 may not substantially affect the physiological function of GDF8. A comprehensive understanding of the molecular mechanisms underlying trophoblast invasion is pivotal for the development of new diagnostic and therapeutic strategies to prevent and treat pregnancy-related complications, such as preeclampsia. In the present study, we also aimed to investigate the underlying mechanisms by which GDF8 upregulates the expression of FSTL3 in human trophoblast cells. In the canonical signaling pathway, GDF8 ligand initially binds to two type II receptors (activin type II receptors), ActRIIA and ActRIIB (Lee and McPerron, 2001). However, the downstream signaling mediator is mainly determined by the activation of the TGF-β type I receptor (Hata and Chen, 2016). Using an siRNA-mediated inhibition approach, we showed that depletion of ALK5 completely abolished the GDF8-induced increases in the phosphorylated protein levels of SMAD2 and SMAD3. Most importantly, ALK5 depletion completely abolished the GDF8-induced upregulation of FSTL3 expression. However, siRNA knockdown of ALK4 did not have these effects. These findings indicate that ALK5, but not ALK4 is the principal type I receptor that mediates the GDF8-induced cellular activities in human trophoblasts. Consistent with these results, previous studies have shown that ALK5 also mediates the GDF8-induced cellular action in human granulosa cells (Chang et al., 2016a,c). Here we demonstrated that in placenta, GDF8 promotes FSTL3 expression and production via the activation of the SMAD2/3 signaling pathway. The GDF8-induced upregulation of FSTL3 expression can be completely abolished after knockdown of either SMAD2 or SMAD3.
Proposed model of the stimulatory effect of growth differentiation factor 8 (GDF8) on relative transwell cells in human trophoblast cells. GDF8 binds to a heterotetrameric receptor complex comprised of type I (ALK5) and type II receptors. Ligand-induced activation of the receptor complex results in the phosphorylation and activation of ALK5, leading to the activation of receptor-regulated SMAD2 and SMAD3. Phosphorylated SMAD2 and SMAD3 form a heterotrimeric complex with common SMAD4 that translocates into the nucleus where it binds the FSTL3 promoter and stimulates the transcription and secretion of FSTL3, which in turn promotes cell invasion of human trophoblast cells.

DATA AVAILABILITY STATEMENT
All datasets generated in this study are included in the article/supplementary material.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Research Ethics Board of the University of British Columbia. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
JX, HZ, MD, and PL conceived and designed research. JX and HZ performed experiments and drafted manuscript. JX, HZ, and H-MC analyzed data. JX, H-MC, CK, MD, and PL interpreted results of experiments. MD and PL edited and revised manuscript. JX, HZ, H-MC, CK, MD, and PL approved final version of manuscript. All authors contributed to the article and approved the submitted version.
ACKNOWLEDGMENTS

We thank the patients and staff of the CARE program at the BC Women’s Hospital & Health Centre for providing the placental samples used in this study.

REFERENCES

Adu-Gyami, E. A., Ding, Y. B., and Wang, Y. X. (2020). Regulation of placental transformation by the transforming growth factor beta superfamily. Biol. Reprod. 102, 18–26. doi: 10.1093/biolre/ioz186

Allias, F., Bolze, P. A., Gaillot-Durand, L., and Devoasoux-Shishboran, M. (2015). Gestational trophoblastic disease. Anna. De Pathol. 34, 434–447. doi: 10.1016/j.anapat.2014.09.004

Attisano, L., Carcamo, J., Ventura, F., Weis, F. M., Massague, J., and Wrana, J. L. (1993). Identification of human activin and TGF beta type 1 receptors that form heteromeric kinase complexes with type II receptors. Cell 75, 671–680. doi: 10.1021/09867493900488–C

Bischof, P., and Campana, A. (2000). Molecular mediators of implantation. Baill. Best Pract. Res. Clin. Obstet. Gynaecol. 14, 801–814. doi: 10.1053/beog.2000.0120

Brandt, C., Anders, R. N., Christian, P. F., Jakob, H., Bente, K. P., and Peter, P. (2007). Endovascular trophoblast invasion: a regulatory network for the protection of pregnancy. Sem. Perinatol. 31, 55–66. doi: 10.1053/j.semperi.2009.02.010

Burrows, T. D., King, A., Fau-Loke, Y. W., and Loke, Y. W. (1995). Decidua in human placental implantation. Hum. Reprod Update 2, 1355–4786. doi: 10.1093/humupd/2.4.307

Burns, B. J., and Osmun, D. R. (2009). Gestational trophoblastic disease. J. Obstet. Gynaecol. 39, 1210–1216. doi: 10.3109/08242970903491890

Conley, Y. P. (2011). Gene expression in first trimester preeclampsia placenta. Reprod. Sci. 18, 134–139. doi: 10.1177/10998004110385448

Douda, J., and Osei-Hyiaman, D. (2015). Follistatin-like-3 and myostatin in skeletal muscle from type 2 diabetes and relatives: differential regulation of insulin signaling pathways. J. Clin. Endocrinol. Metab. 99, E2215–E2227. doi: 10.1210/jc.2014-2134

Faivre, S., et al. (2014). Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 5, 78–94. doi: 10.18632/oncotarget.1569

Founds, S. A., Terhorst, L. A., Conrad, K. P., Hogge, W. A., Jeyabalan, A., and Conley, Y. P. (2011). Gene expression in first trimester placenta. Biol. Res. Nurs. 13, 130–137. doi: 10.1016/j.jemepi.2009.02.010

Founds, S. A., Ren, D., Roberts, J. M., Osmun, D. R., and Powers, R. W. (2015). Follistatin-like-3 across gestation in preeclampsia and uncomplicated pregnancies among lean and obese women. Reprod Sci. 22, 402–409. doi: 10.1177/1933719145283732

Guo, J., Tian, T., Lu, D., Xia, G., Wang, H., Dong, M., et al. (2012). Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia. J. Obstet. Gynaecol. Res. 38, 988–996. doi: 10.1111/j.1447-0756.2011.01823.x

Hata, A., and Chen, Y. G. (2016). TGF-β Signaling from Receptors to Smads. Cold Spring Harb Perspect Biol. 8:e202061. doi: 10.1101/cshperspect.a202061

Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., and Hougard, J. A. (2009). Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 58, 30–38. doi: 10.2337/db08-0943

Hormuth, R., Maki, M., Zsengeller, Z., Lo, A., Peronne, E., Rigo, J., et al. (2016). 15 Follistatin-Like 3 Protein (FSTL3) is upregulated in preeclampsia: Biomarkers, prediction of preeclampsia. Preg. Hypertens. Int. J. Women Cardiovasc. Health 6:144. doi: 10.1016/j.preghy.2016.08.016

Irving, J. A., Lysiak, J. J., Graham, C. H., Hearn, S., Han, V. K., and Lala, P. K. (1993). Characteristics of trophoblast cells migrating from first trimester chorionic villus explants and propagated in culture. Placenta 14, 433–433. doi: 10.1016/0143-4004(93)90010-0

Justus, C. R., Leffler, N., Ruiz-Echevarria, M., and Yang, L. V. (2014). In vitro cell migration and invasion assays. J. Vis. Exp. 88:51046. doi: 10.1379/jvi.s.051046

Karumanchi, S. A., and Stillman, I. E. (2006). In vivo rat model of preeclampsia. Methods Mol. Biol. 122, 393–399. doi: 10.3855/59259-989-3-393

Kauffmann, P., Black, S., and Huppertz, B. (2003). Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reprod 69, 1–7. doi: 10.1095/biolreprod.102.014977

Lee, S. J., and McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U S A 98, 9306–9311. doi: 10.1073/pnas.151270098

Li, Y., Klausen, C., Cheng, J. C., Zhu, H., and Leung, P. C. (2014). Activin A and AB increase human trophoblast cell invasion by up-regulating N-cadherin. J. Clin. Endocrinol. Metab. 99, E2216–E2225. doi: 10.1210/jc.2014-2118

Li, Y., Klausen, C., Zhu, H., and Leung, P. C. (2015). Activin A Increases Human Trophoblast Invasion by Inducing SNAIL-Mediated MMP2 Up-Regulation Through ALK4. J. Clin. Endocrinol. Metab. 100, E1415–E1427. doi: 10.1210/jc.2015-2134

Loke, Y. W., King, A., Burrows, T. D., and Burrows, T. D. (1995). Decidua in human implantation. Hum. Reprod (Suppl. 2), 14–21. doi: 10.1093/humrep/deu.1421

McPherron, A. C., Lawler, A. M., and Lee, S.-J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387, 83–90. doi: 10.1038/387083a0

Mitchell, D. M., Osepechouk, C. C., Leung, K.-C., Leung, K. C., McMahon, C. D., and Bass, J. J. (2006). Myostatin is a human placental product that regulates glucose uptake. Physiol. Rep. 6:e13837. doi: 10.1210/jc.2005-2361

Neuzillet, C., de Gramont, A., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., et al. (2014). Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 5, 78–94. doi: 10.18632/oncotarget.1569

Oshima, Y., Ouchi, N., Shimano, M., Pimentel, D. R., Papanicolaou, K. N., Paré, K. D., et al. (2009). Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 120, 1606–1615. doi: 10.1161/CIRCULATIONAHA.109.872200

Peiris, H. N., Georgiou, H., Lappas, M., Kaitu’u-Lino, T., Salomón, C., Vaswani, K., et al. (2015). Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production
by First-Trimester Placental Explants Following Myostatin Treatment. Reprod Sci. 22, 1202–1211. doi: 10.1177/1933719115572482
Peiris, H. N., and Mitchell, M. D. (2012). The expression and potential functions of placental myostatin. Placenta 33, 902–907. doi: 10.1016/j.placenta.2012.06.021
Peiris, H. N., Salomon, C., Payton, D., Ashman, K., Vaswani, K., Chan, A., et al. (2014). Myostatin is localized in extravillous trophoblast and up-regulates migration. J. Clin. Endocrinol. Metab. 99, E2288–E2297. doi: 10.1210/jc.2014-2615
Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J., and Attisano, L. (2003). Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell Biol. 23, 7230–7242. doi: 10.1128/MCB.23.20.7230-7242.2003
Redman, C. W., and Sargent, I. L. (2005). Latest advances in understanding preeclampsia. Science 308, 1095–1098. doi: 10.1126/science.1111726
Runhua, M., Qiang, J., Yunqing, S., Wenjun, D., and Chunsheng, W. (2019). FSTL3 Induces Lipid Accumulation and Inflammatory Response in Macrophages and Associates With Atherosclerosis. J. Cardiovasc. Pharmacol. 74, 566–573. doi: 10.1097/FJC.0000000000000742
Schneyer, A., Sidis, Y., Xia, Y., Saito, S., del Re, E., et al. (2004). Differential actions of follistatin and follistatin-like 3. Mol. Cell Endocrinol. 225, 25–28. doi: 10.1016/j.mce.2004.02.009
Shi, Y., and Massagué, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685–700. doi: 10.1016/S0092-8674(03)00432-X
Silva, J. F., and Serakides, R. (2016). Intrauterine trophoblast migration: A comparative view of humans and rodents. Cell Adh. Migr. 10, 88–110. doi: 10.1080/19336918.2015.1120397
Song, B., Estrada, K. D., and Lyons, K. M. (2009). Smad signaling in skeletal development and regeneration. Cytok. Growth Fact. Rev. 20, 379–388. doi: 10.1016/j.cytogfr.2009.10.010
Staun-Ram, E., and Shalev, E. (2005). Human trophoblast function during the implantation process. Rep. Biol. Endocrinol. 3:56. doi: 10.1186/1477-7827-3-56
Tortoriello, D. V., Sidis, Y., Holtzman, D. A., Holmes, W. E., and Schneyer, A. L. (2001). Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology 142, 3426–3434. doi: 10.1210/endo.142.8.8319
Tsuchida, K. (2004). Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr. Drug Target. Immunol. Endocr. Metabol. Disord. 4, 157–166. doi: 10.2174/1568008043339901
Xie, J., Xu, Y., Wang, L., Wang, P., Wang, M., and Dong, M. (2018). Involvement of follistatin-like 3 in preeclampsia. Biochem. Biophys. Res. Commun. 506, 692–697. doi: 10.1016/j.bbrc.2018.10.139
Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., et al. (2018). Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor. Oncotarget 9, 6659–6677. doi: 10.18632/oncotarget.23795
Zhu, J. Y., Pang, Z. J., and Yu, Y. H. (2012). Regulation of trophoblast invasion: the role of matrix metalloproteinases. Rev. Obstet. Gynecol. 5, e137–e143.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Xie, Zhu, Chang, Klausen, Dong and Leung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.